Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2009

Open Access 01-12-2009 | Research

The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer

Authors: Yan-Fang Gao, Rui-Qing Peng, Jiang Li, Ya Ding, Xing Zhang, Xiao-Jun Wu, Zhi-Zhong Pan, De-Sen Wan, Yi-Xin Zeng, Xiao-Shi Zhang

Published in: Journal of Translational Medicine | Issue 1/2009

Login to get access

Abstract

Background

One of the putative mechanisms of tumor immune escape is based on the hypothesis that carcinomas actively create an immunosuppressed state via the expression of indoleamine 2,3-dioxygenase (IDO), both in the cancer cells and in the immune cells among the tumor-draining lymph nodes (TDLN). In an attempt to verify this hypothesis, the patterns of expression of IDO in the cancer cells and the immune cells among colon cancers were examined.

Methods

Seventy-one cases of pathologically-confirmed colon cancer tissues matched with adjacent non-cancerous tissues, lymph node metastases, and TDLN without metastases were collected at the Sun Yat-sen Cancer Center between January 2000 and December 2000. The expression of IDO and Bin1, an IDO regulator, was determined with an immunohistochemical assay. The association between IDO or Bin1 expression and TNM stages and the 5-year survival rate in colon cancer patients was analyzed.

Results

IDO and Bin1 were detected in the cytoplasm of cancer cells and normal epithelium. In primary colon cancer, the strong expression of IDO existed in 9/71 cases (12.7%), while the strong expression of Bin1 existed in 33/71 cases (46.5%). However, similar staining of IDO and Bin1 existed in the adjacent non-cancerous tissues. Among the 41 cases with primary colon tumor and lymph node metastases, decreased expression of IDO was documented in the lymph node metastases. Furthermore, among the TDLN without metastases, a higher density of IDO+cells was documented in 21/60 cases (35%). Both univariate and multivariate analyses revealed that the density of IDO+cells in TDLN was an independent prognostic factor. The patients with a higher density of IDO+cells in TDLN had a lower 5-year survival rate (37.5%) than the cells with a lower density (73.1%).

Conclusion

This study demonstrated paradoxical patterns of expression of IDO in colon cancer. The high density IDO+cells existed in TDLN and IDO was down-regulated in lymph nodes with metastases, implying that IDO in tumor and immune cells functions differently.
Appendix
Available only for authorised users
Literature
1.
2.
Takikawa O: Biochemical and medical aspects of the indoleamine 2,3-dioxy-genase-initiated L-tryptophan metabolism. Biochem Biophys Res Commun. 2005, 338 (1): 12-19. 10.1016/j.bbrc.2005.09.032.CrossRefPubMed
3.
King NJ, Thomas SR: Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol. 2007, 39 (12): 2167-2172. 10.1016/j.biocel.2007.01.004.CrossRefPubMed
4.
Munn DH: Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol. 2006, 18 (2): 220-225. 10.1016/j.coi.2006.01.002.CrossRefPubMed
5.
Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL: Prevention of allogeneic fetal rejection by tryptophancatabolism. Science. 1998, 281 (5380): 1191-1193. 10.1126/science.281.5380.1191.CrossRefPubMed
6.
Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004, 4 (10): 762-774. 10.1038/nri1457.CrossRefPubMed
7.
Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, Trucco M: Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes. 2002, 51 (2): 356-365. 10.2337/diabetes.51.2.356.CrossRefPubMed
8.
Jalili RB, Rayat GR, Rajotte RV, Ghahary A: Suppression of islet allogeneic immune response by indoleamine 2,3 dioxygenase-expressing fibroblasts. J Cell Physiol. 2007, 213 (1): 137-143. 10.1002/jcp.21100.CrossRefPubMed
9.
Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, Takabayashi K, Broide DH, Carson DA, Raz E: Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest. 2004, 114 (2): 270-279.PubMedCentralCrossRefPubMed
10.
Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Eynde Van den BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003, 9 (10): 1269-1274. 10.1038/nm934.CrossRefPubMed
11.
Zheng X, Koropatnick J, Li M, Zhang X, Ling F, Ren X, Hao X, Sun H, Vladau C, Franek JA, Feng B, Urquhart BL, Zhong R, Freeman DJ, Garcia B, Min WP: Reinstalling antitumor immunity by inhibiting tumor-derived immuno-suppressive molecule IDO through RNA interference. J Immunol. 2006, 177 (8): 5639-5646.CrossRefPubMed
12.
Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, Nagasaka T, Takikawa O, Kikkawa F: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 2006, 95 (11): 1555-1561. 10.1038/sj.bjc.6603477.PubMedCentralCrossRefPubMed
13.
Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Göbel G, Margreiter R, Königsrainer A, Fuchs D, Amberger A: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006, 12 (4): 1144-1151. 10.1158/1078-0432.CCR-05-1966.CrossRefPubMed
14.
Chen PW, Mellon JK, Mayhew E, Wang S, He YG, Hogan N, Niederkorn JY: Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion. Exp Eye Res. 2007, 85 (5): 617-625. 10.1016/j.exer.2007.07.014.PubMedCentralCrossRefPubMed
15.
Sedlmayr P, Semlitsch M, Gebru G, Karpf E, Reich O, Tang T, Wintersteiger R, Takikawa O, Dohr G: Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix. Adv Exp Med Biol. 2003, 527: 91-95.CrossRefPubMed
16.
Karanikas V, Zamanakou M, Kerenidi T, Dahabreh J, Hevas A, Nakou M, Gourgoulianis KI, Germenis AE: Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther. 2007, 6 (8): 1258-262.CrossRefPubMed
17.
Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC: Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008, 134 (11): 1247-1253. 10.1007/s00432-008-0395-1.CrossRefPubMed
18.
Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W: Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res. 2007, 13 (23): 6993-7002. 10.1158/1078-0432.CCR-07-0942.CrossRefPubMed
19.
Takao M, Okamoto A, Nikaido T, Urashima M, Takakura S, Saito M, Saito M, Okamoto S, Takikawa O, Sasaki H, Yasuda M, Ochiai K, Tanaka T: Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep. 2007, 17 (6): 1333-1339.PubMed
20.
Travers MT, Gow IF, Barber MC, Thomson J, Shennan DB: Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells. Biochim Biophys Acta. 2004, 1661 (1): 106-12. 10.1016/j.bbamem.2003.12.004.CrossRefPubMed
21.
Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O, Kikkawa F: Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res. 2008, 14 (8): 2310-2317. 10.1158/1078-0432.CCR-07-4144.CrossRefPubMed
22.
Munn DH, Mellor AL: The tumor-draining lymph node as an immune-privileged site. Immunol Rev. 2006, 213: 146-158. 10.1111/j.1600-065X.2006.00444.x.CrossRefPubMed
23.
Terness P, Chuang JJ, Opelz G: The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol. 2006, 27: 68-73. 10.1016/j.it.2005.12.006.CrossRefPubMed
24.
Löb S, Königsrainer A: Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?. Langenbecks Arch Surg. 2008, 393 (6): 995-1003. 10.1007/s00423-007-0245-7.CrossRefPubMed
25.
Negin B, Panka D, Wang W, Siddiqui M, Tawa N, Mullen J, Tahan S, Mandato L, Polivy A, Mier J, Atkins M: Effect of melanoma on immune function in the regional lymph node basin. Clin Cancer Res. 2008, 14 (3): 654-659. 10.1158/1078-0432.CCR-07-1577.CrossRefPubMed
26.
Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, Lei HY, Lai MD: A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res. 2009, 15: 641-649. 10.1158/1078-0432.CCR-08-1988.CrossRefPubMed
27.
Ou X, Cai S, Liu P, Zeng J, He Y, Wu X, Du J: Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol. 2008, 134: 525-533. 10.1007/s00432-007-0315-9.CrossRefPubMed
28.
Miyazaki T, Moritake K, Yamada K, Hara N, Osago H, Shibata T, Akiyama Y, Tsuchiya M: Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. J Neurosurg. 2009,
29.
Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH: Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007, 67 (2): 792-801. 10.1158/0008-5472.CAN-06-2925.CrossRefPubMed
30.
MacKenzie CR, Heseler K, Müller A, Däubener W: Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines. Curr Drug Metab. 2007, 8 (3): 237-244. 10.2174/138920007780362518.CrossRefPubMed
31.
Burke F, Knowles RG, East N, Balkwill FR: The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int J Cancer. 1995, 60 (1): 115-122. 10.1002/ijc.2910600117.CrossRefPubMed
32.
Gasparri AM, Jachetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP, Traversari C, Bellone M, Corti A: Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma. Mol Cancer Ther. 2008, 7 (12): 3859-3866. 10.1158/1535-7163.MCT-08-0538.CrossRefPubMed
33.
Melichar B, Hu W, Patenia R, Melicharová K, Gallardo ST, Freedman R: rIFN-gamma-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition. J Transl Med. 2003, 1 (1): 5-10.1186/1479-5876-1-5.PubMedCentralCrossRefPubMed
34.
Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, Barda AK, Gourgoulianis KI, Germenis AE: Foxp3 expression in human cancer cells. J Transl Med. 2008, 6: 19-10.1186/1479-5876-6-19.PubMedCentralCrossRefPubMed
35.
36.
Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C: Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med. 2007, 5: 62-10.1186/1479-5876-5-62.PubMedCentralCrossRefPubMed
37.
Gastl G, Spizzo G, Obrist P, Dünser M, Mikuz G: Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet. 2000, 356 (9246): 1981-1982. 10.1016/S0140-6736(00)03312-2.CrossRefPubMed
38.
Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007, 117 (9): 2570-2582. 10.1172/JCI31911.PubMedCentralCrossRefPubMed
39.
von Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel MS, Fiore F, Roth U, Beyer M, Debey S, Wickenhauser C, Hanisch FG, Schultze JL: CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood. 2006, 108 (1): 228-237. 10.1182/blood-2005-08-3507.CrossRefPubMed
40.
Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004, 114 (2): 280-290.PubMedCentralCrossRefPubMed
41.
Kahler DJ, Mellor AL: T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase. Handb Exp Pharmacol. 2009, 188: 165-196. full_text.CrossRefPubMed
42.
Liu JY, Zhang XS, Ding Y, Peng RQ, Cheng X, Zhang NH, Xia JC, Zeng YX: The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice. J Transl Med. 2005, 3 (1): 5-10.1186/1479-5876-3-5.PubMedCentralCrossRefPubMed
43.
Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H: Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006, 213: 131-145. 10.1111/j.1600-065X.2006.00442.x.CrossRefPubMed
44.
Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6 (4): 295-307. 10.1038/nri1806.CrossRefPubMed
45.
Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, Cohen PA, Shu S: Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol. 2008, 181 (5): 3291-300.CrossRefPubMed
46.
Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, McCormick D, Jager MJ, Cree IA: Mechanisms of local immuno-suppression in cutaneous melanoma. Br J Cancer. 2007, 96 (12): 1879-1887. 10.1038/sj.bjc.6603763.PubMedCentralCrossRefPubMed
47.
Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH, Riordan NH, Koropatnick J, Bogin V, Minev BR, Min WP, Tullis RH: Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med. 2008, 6: 37-10.1186/1479-5876-6-37.PubMedCentralCrossRefPubMed
48.
Huber V, Filipazzi P, Iero M, Fais S, Rivoltini L: More insights into the immunosuppressive potential of tumor exosomes. J Transl Med. 2008, 6: 63-10.1186/1479-5876-6-63.PubMedCentralCrossRefPubMed
49.
Fallarino F, Gizzi S, Mosci P, Grohmann U, Puccetti P: Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. Curr Drug Metab. 2007, 8 (3): 209-216. 10.2174/138920007780362581.CrossRefPubMed
50.
Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005, 11 (3): 312-319. 10.1038/nm1196.CrossRefPubMed
51.
Prendergast GC: Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 2008, 27 (28): 3889-3900. 10.1038/onc.2008.35.CrossRefPubMed
52.
Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ, Brody JR: Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg. 2008, 206 (5): 849-54. 10.1016/j.jamcollsurg.2007.12.014.CrossRefPubMed
53.
Zamanakou M, Germenis AE, Karanikas V: Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett. 2007, 111 (2): 69-75. 10.1016/j.imlet.2007.06.001.CrossRefPubMed
54.
Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, Isobe K, Kikkawa F: Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res. 2008, 14 (22): 7251-7259. 10.1158/1078-0432.CCR-08-0991.CrossRefPubMed
55.
Battaglia A, Buzzonetti A, Baranello C, Ferrandina G, Martinelli E, Fanfani F, Scambia G, Fattorossi A: Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother. 2009, 58 (9): 1363-73. 10.1007/s00262-008-0646-7.CrossRefPubMed
56.
Löb S, Königsrainer A, Rammensee HG, Opelz G, Terness P: Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?. Nat Rev Cancer. 2009, 9 (6): 445-52. 10.1038/nrc2639.CrossRefPubMed
Metadata
Title
The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer
Authors
Yan-Fang Gao
Rui-Qing Peng
Jiang Li
Ya Ding
Xing Zhang
Xiao-Jun Wu
Zhi-Zhong Pan
De-Sen Wan
Yi-Xin Zeng
Xiao-Shi Zhang
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2009
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-7-71

Other articles of this Issue 1/2009

Journal of Translational Medicine 1/2009 Go to the issue

Research

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

Review

RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation

Research

Optical imaging of the peri-tumoral inflammatory response in breast cancer

Research

Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer

Research

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma

Methodology

Evolutionary concepts in biobanking - the BC BioLibrary
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits